Close Noetik Faster: SAB Expansion Fuels AI Biomarker Pitch

🚀 Battle Card: Noetik

• William Grossman, M.D., Ph.D., Scientific Advisory Board Member · 🔗 [LinkedIn](https://www.linkedin.com/company/noetik-inc/)

• This Noetik sales trigger underscores a move to de-risk clinical programs and secure top translational insight at scale. → Source

• Accelerating therapeutic program progression toward clinic

• Ensuring robust regulatory and translational strategies

• Primary: AI-powered biomarker discovery platform → Reduce time to target identification; a key Noetik sales trigger benefit

• Expansion: High-throughput spatial data integration → Improve patient stratification and trial success

• HQ: San Francisco, CA

• Employees: ≈ 150

• Rev: ≈ $50M

• Website: [https://www.noetik.ai](https://www.noetik.ai)

🤼 Competitive Intel

• Recursion — AI-driven drug discovery
• Unique edge: Massive in-house screening library
• Evaluated by R&D for rapid hypothesis testing

• Insitro — ML-based biology platform
• Unique edge: Genotype-phenotype modeling at scale
• Evaluated by Translational Sciences for early indication mapping

• Atomwise — Structure-based AI screening
• Unique edge: Strong track record in small-molecule hits
• Evaluated by Chemistry and Biology leads for lead optimization

• BenevolentAI — Knowledge graph and AI inference
• Unique edge: Integrated scientific graph for target ID
• Evaluated by Translational Medicine for target validation

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑AI-powered biomarker discovery platform❑
PROOF_METRIC  = ❑Reduced target identification time by 30%❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = William
COMPANY     = Noetik
DEPT        = Scientific Advisory Board
SIZE        = ≈ 150
BOTTLENECK  = Slow progression toward clinic
EVENT       = Expands Scientific Advisory Board
DETAIL      = Appointment of William Grossman to SAB
PAIN        = Accelerating therapeutic program progression toward the clinic
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251001739674&div=41152219
SIM_CO      = Recursion
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 150
REV_EST     = ≈ $50M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ 150-person Scientific Advisory Board

William—noticed your Scientific Advisory Board team is ≈ 150.

That’s when Slow progression toward clinic slows growth.

We helped Recursion fix this with AI-powered biomarker discovery platform.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Appointment of William Grossman to SAB — Accelerating therapeutic program progression toward the clinic.  
AI-powered biomarker discovery platform. Reduced target identification time by 30%.  
Quick chat?